Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a retrospective cohort study

Asadi et al., Journal of Pharmaceutical Policy and Practice, doi:10.1186/s40545-023-00511-w
Jan 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
Retrospective 660 hospitalized patients in Iran comparing 6 different drug regimens: 1. HCQ or CQ+AZ, 2. interferons (ReciGen/Ziphron) or interferon + Kaletra (lopinavir/ritonavir), 3. atazanavir, 4. remdesivir, 5. favipiravir, and 6. corticosteroids (dexamethasone/methylprednisolone).
Results show lower risk for HCQ/CQ+AZ in 20 of 25 comparisons (5 outcomes and 5 alternate regimens), with statistical significance in only two cases.
Asadi et al., 16 Jan 2023, retrospective, Iran, peer-reviewed, 7 authors, study period February 2020 - February 2021. Contact: moradi_gh@yahoo.com.
This PaperHCQAll
Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a retrospective cohort study
Jalal Asadi, Mohammad Aziz Rasouli, Ebrahim Ghaderi, Daem Roshani, Behzad Mohsenpour, Yousef Moradi, Ghobad Moradi
Journal of Pharmaceutical Policy and Practice, doi:10.1186/s40545-023-00511-w
Objectives Different drugs have different effects on the prognosis of patients with COVID-19. This study aimed to evaluate the effect of different drug regimens on patients with COVID-19, hospitalized in Sanandaj city. Methods In this retrospective cohort study, 660 patients with COVID-19, hospitalized in the Tohid, Kowsar and Besat hospitals located Sanandaj (Kurdistan Province, Iran) were studied from February 2020 to February 2021 with clinical symptoms and positive test results. Results The results of multivariate regression analysis showed the days of hospitalization for patients who had received the drug regimen 2 (Interferons (ReciGen/Ziphron) or Interferon Vectra (lopinavir/ritonavir)) was 1.92 times higher than those who had received the drug regimen 1 (hydroxychloroquine group or a combination of chloroquine and azithromycin) while a significant association was observed (OR = 1.92, 95% CI: 1.16-3.16, P = 0.011). Also, the hospitalization in ICU was longer in patients treated by the drug regimen 2 (Interferons (ReciGen/Ziphron) or Interferon Vectra (lopinavir/ritonavir)) (OR = 4.63, 95% CI: 1.80-11.82, P = 0.001), however, drug regimens did not show a significant effect on mortality and use of ventilator in patients (P > 0.05). Conclusion The study results showed the drug regimens 2 and 5 increased the days of hospitalization and hospitalization in ICU, respectively, while the other drug regimens had no significant effect on mortality and use a ventilator in the studied patients and none of the drug regimens had an effect on reducing mortality compared to other ones.
Abbreviations HIS Declarations Ethics approval and consent to participate The Ethics Committee of Kurdistan University of Medical Sciences (IR.MUK. REC.1399.316) reviewed and approved this study. (All patients provided written informed consents. The relevant guidelines and regulations performed all methods.) Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. • fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year • At BMC, research is always in progress. Learn more biomedcentral.com/submissions Ready to submit your research Ready to submit your research ? Choose BMC and benefit from: ? Choose BMC and benefit from: Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Adeli, Fesharaki, Evaluation of COVID-19 treatment outcomes in a military hospital and its comparison with a nonmilitary hospital, Journal Mil Med
Almazrou, Almalki, Alanazi, Alqahtani, Alghamd, Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: a retrospective cohort study, Saudi Pharmaceutical Journal
Ansems, Grundeis, Dahms, Mikolajewska, Thieme et al., Remdesivir for the treatment of COVID-19, Cochrane Database Syst Rev, doi:10.1002/14651858.CD014962
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis
Assiri, Iqbal, Mohammed, Alsaleh, Assiri et al., COVID-19 related treatment and outcomes among COVID-19 ICU patients: a retrospective cohort study, J Infect Public Health
Bahl, Johnson, Chen, Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients, Intern Emerg Med
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavirritonavir in adults hospitalized with severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Ceylan, Estimation of COVID-19 prevalence in Italy, Spain, and France, Sci Total Environ
Chibber, Haq, Ahmed, Andrabi, Singh, Advances in the possible treatment of COVID-19: a review, Eur J Pharmacol
Cunningham, Goh, Koh, Treatment of COVID-19: old tricks for new challenges, Crit Care, doi:10.1186/s13054-020-2818-6
Felsenstein, Herbert, Mcnamara, Hedrich, COVID-19: immunology and treatment options, Clin Immunol
Garibaldi, Wang, Robinson, Zeger, Bandeen-Roche et al., Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19, JAMA Netw Open
Gautret, Lagier, Parola, Meddeb, Mailhe et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med
Guner, Hasanoglu, Kayaaslan, Aypak, Akinci et al., Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir, J Infect Public Health
Haider, Gour, Pandey, Kanwar, Tiwari et al., COVID-19 infection: targeting possibilities for treatment. Critical reviews ™ in therapeutic drug carrier systems, Crit Rev Ther Drug Carrier Syst
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials, Sci Rep
Ismail, Jamil, Rahman, Bakar, Saad et al., The implementation of Hospital Information System (HIS) in tertiary hospitals in Malaysia: a qualitative study, Malays J Public Health Med
Jean, Lee, Hsueh, Treatment options for COVID-19: the reality and challenges, J Microbiol Immunol Infect
Joshi, Parkar, Ansari, Vora, Talwar et al., Role of favipiravir in the treatment of COVID-19, Int J Infect Dis
Keller, Kitsis, Arora, Chen, Agarwal et al., Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19, J Hosp Med
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis, Travel Med Infect Dis
Li, Liao, Zhou, Wang, Yang et al., Comparison of associations between glucocorticoids treatment and mortality in COVID-19 patients and SARS patients: a systematic review and meta-analysis, Shock
Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, Med
Nojomi, Yassin, Keyvani, Makiani, Roham et al., Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial, BMC Infect Dis
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA
Saba, Elsheikh, Forecasting the prevalence of COVID-19 outbreak in Egypt using nonlinear autoregressive artificial neural networks, Process Saf Environ Prot
Somers, Eschenauer, Troost, Golob, Gandhi et al., Tocilizumab for treatment of mechanically ventilated patients with COVID-19, Clin Infect Dis
Stasi, Fallani, Voller, Silvestri, Treatment for COVID-19: An overview, Eur J Pharmacol, doi:10.1016/j.ejphar.2020.173644
Tong, Su, Yu, Wu, Chen et al., Ribavirin therapy for severe COVID-19: a retrospective cohort study, Int J Antimicrob Agents
Vahedi, Ghanei, Ghazvini, Azadi, Izadi et al., The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study, DARU J Pharm Sci
Wani, Clinical profile and outcome of covid positive obstetric patients in a tertiary care hospital-a retrospective study, Online J Health Allied Sci
Wissel, Camp, Kouril, Weis, Glauser et al., An interactive online dashboard for tracking COVID-19 in U.S. counties, cities, and states in real time, J Am Med Inform Assoc
Ye, Wang, Colunga-Lozano, Prasad, Tangamornsuksan et al., Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis, CMAJ
Yu, Salvador, Melani, Berg, Neblett et al., Racial residential segregation and economic disparity jointly exacerbate COVID-19 fatality in large American cities, Ann N Y Acad Sci, doi:10.1111/nyas.14567
Zhong, Wang, Zhang, Liu, Le et al., Efficacy and safety of current therapeutic options for COVID-19-lessons to be learnt from SARS and MERS epidemic: a systematic review and meta-analysis, Pharmacol Res
{ 'DOI': '10.1186/s40545-023-00511-w', 'ISSN': ['2052-3211'], 'URL': 'http://dx.doi.org/10.1186/s40545-023-00511-w', 'abstract': '<jats:title>Abstract</jats:title><jats:sec>\n' ' <jats:title>Objectives</jats:title>\n' ' <jats:p>Different drugs have different effects on the prognosis of patients ' 'with COVID-19. This study aimed to evaluate the effect of different drug regimens on patients ' 'with COVID-19, hospitalized in Sanandaj city.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>In this retrospective cohort study, 660 patients with COVID-19, ' 'hospitalized in the Tohid, Kowsar and Besat hospitals located Sanandaj (Kurdistan Province, ' 'Iran) were studied from February 2020 to February 2021 with clinical symptoms and positive ' 'test results.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>The results of multivariate regression analysis showed the days of ' 'hospitalization for patients who had received the drug regimen 2 (Interferons ' '(ReciGen/Ziphron) or Interferon Vectra (lopinavir/ritonavir)) was 1.92 times higher than ' 'those who had received the drug regimen 1 (hydroxychloroquine group or a combination of ' 'chloroquine and azithromycin) while a significant association was observed (OR\u2009=\u2009' '1.92, 95% CI: 1.16–3.16, <jats:italic>P</jats:italic>\u2009=\u20090.011). Also, the ' 'hospitalization in ICU was longer in patients treated by the drug regimen 2 (Interferons ' '(ReciGen/Ziphron) or Interferon Vectra (lopinavir/ritonavir)) (OR\u2009=\u20094.63, 95% CI: ' '1.80–11.82, <jats:italic>P</jats:italic>\u2009=\u20090.001), however, drug regimens did not ' 'show a significant effect on mortality and use of ventilator in patients ' '(<jats:italic>P</jats:italic>\u2009&gt;\u20090.05).</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>The study results showed the drug regimens 2 and 5 increased the days ' 'of hospitalization and hospitalization in ICU, respectively, while the other drug regimens ' 'had no significant effect on mortality and use a ventilator in the studied patients and none ' 'of the drug regimens had an effect on reducing mortality compared to other ones.</jats:p>\n' ' </jats:sec>', 'alternative-id': ['511'], 'article-number': '4', 'assertion': [ { 'group': {'label': 'Article History', 'name': 'ArticleHistory'}, 'label': 'Received', 'name': 'received', 'order': 1, 'value': '5 July 2022'}, { 'group': {'label': 'Article History', 'name': 'ArticleHistory'}, 'label': 'Accepted', 'name': 'accepted', 'order': 2, 'value': '4 January 2023'}, { 'group': {'label': 'Article History', 'name': 'ArticleHistory'}, 'label': 'First Online', 'name': 'first_online', 'order': 3, 'value': '16 January 2023'}, {'group': {'label': 'Declarations', 'name': 'EthicsHeading'}, 'name': 'Ethics', 'order': 1}, { 'group': {'label': 'Ethics approval and consent to participate', 'name': 'EthicsHeading'}, 'name': 'Ethics', 'order': 2, 'value': 'The Ethics Committee of Kurdistan University of Medical Sciences ' '(IR.MUK.REC.1399.316) reviewed and approved this study. (All patients provided ' 'written informed consents. The relevant guidelines and regulations performed ' 'all methods.)'}, { 'group': {'label': 'Consent for publication', 'name': 'EthicsHeading'}, 'name': 'Ethics', 'order': 3, 'value': 'Not applicable.'}, { 'group': {'label': 'Competing interests', 'name': 'EthicsHeading'}, 'name': 'Ethics', 'order': 4, 'value': 'The authors declare that they have no competing interests.'}], 'author': [ {'affiliation': [], 'family': 'Asadi', 'given': 'Jalal', 'sequence': 'first'}, {'affiliation': [], 'family': 'Rasouli', 'given': 'Mohammad Aziz', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ghaderi', 'given': 'Ebrahim', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Roshani', 'given': 'Daem', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mohsenpour', 'given': 'Behzad', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Moradi', 'given': 'Yousef', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Moradi', 'given': 'Ghobad', 'sequence': 'additional'}], 'container-title': 'Journal of Pharmaceutical Policy and Practice', 'container-title-short': 'J of Pharm Policy and Pract', 'content-domain': {'crossmark-restriction': False, 'domain': ['link.springer.com']}, 'created': {'date-parts': [[2023, 1, 16]], 'date-time': '2023-01-16T12:03:04Z', 'timestamp': 1673870584000}, 'deposited': { 'date-parts': [[2023, 1, 16]], 'date-time': '2023-01-16T12:11:36Z', 'timestamp': 1673871096000}, 'indexed': {'date-parts': [[2023, 1, 17]], 'date-time': '2023-01-17T06:04:56Z', 'timestamp': 1673935496146}, 'is-referenced-by-count': 0, 'issue': '1', 'issued': {'date-parts': [[2023, 1, 16]]}, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2023, 12]]}}, 'language': 'en', 'license': [ { 'URL': 'https://creativecommons.org/licenses/by/4.0', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2023, 1, 16]], 'date-time': '2023-01-16T00:00:00Z', 'timestamp': 1673827200000}}, { 'URL': 'https://creativecommons.org/licenses/by/4.0', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2023, 1, 16]], 'date-time': '2023-01-16T00:00:00Z', 'timestamp': 1673827200000}}], 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s40545-023-00511-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s40545-023-00511-w/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s40545-023-00511-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '297', 'original-title': [], 'prefix': '10.1186', 'published': {'date-parts': [[2023, 1, 16]]}, 'published-online': {'date-parts': [[2023, 1, 16]]}, 'publisher': 'Springer Science and Business Media LLC', 'reference': [ { 'author': 'N Wani', 'first-page': '10650', 'issue': '3', 'journal-title': 'Online J Health Allied Sci', 'key': '511_CR1', 'unstructured': 'Wani N. Clinical profile and outcome of covid positive obstetric ' 'patients in a tertiary care hospital-a retrospective study. Online J ' 'Health Allied Sci. 2021;20(3):10650.', 'volume': '20', 'year': '2021'}, { 'DOI': '10.1016/j.ijantimicag.2020.105949', 'author': 'P Gautret', 'doi-asserted-by': 'publisher', 'issue': '1', 'journal-title': 'Int J Antimicrob Agents', 'key': '511_CR2', 'unstructured': 'Gautret P, Lagier J-C, Parola P, Meddeb L, Mailhe M, Doudier B, et al. ' 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results ' 'of an open-label non-randomized clinical trial. Int J Antimicrob Agents. ' '2020;56(1): 105949.', 'volume': '56', 'year': '2020'}, { 'DOI': '10.1016/j.jmii.2020.03.034', 'author': 'S-S Jean', 'doi-asserted-by': 'publisher', 'first-page': '436', 'issue': '3', 'journal-title': 'J Microbiol Immunol Infect', 'key': '511_CR3', 'unstructured': 'Jean S-S, Lee P-I, Hsueh P-R. Treatment options for COVID-19: the ' 'reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–43.', 'volume': '53', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2001282', 'author': 'B Cao', 'doi-asserted-by': 'publisher', 'journal-title': 'N Engl J Med', 'key': '511_CR4', 'unstructured': 'Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of ' 'lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl ' 'J Med. 2020. https://doi.org/10.1056/NEJMoa2001282.', 'year': '2020'}, { 'DOI': '10.1111/nyas.14567', 'author': 'Q Yu', 'doi-asserted-by': 'publisher', 'journal-title': 'Ann N Y Acad Sci', 'key': '511_CR5', 'unstructured': 'Yu Q, Salvador CE, Melani I, Berg MK, Neblett EW, Kitayama S. Racial ' 'residential segregation and economic disparity jointly exacerbate ' 'COVID-19 fatality in large American cities. Ann N Y Acad Sci. 2021. ' 'https://doi.org/10.1111/nyas.14567.', 'year': '2021'}, { 'DOI': '10.1093/jamia/ocaa071', 'author': 'BD Wissel', 'doi-asserted-by': 'publisher', 'first-page': '1121', 'issue': '7', 'journal-title': 'J Am Med Inform Assoc', 'key': '511_CR6', 'unstructured': 'Wissel BD, Van Camp PJ, Kouril M, Weis C, Glauser TA, White PS, et al. ' 'An interactive online dashboard for tracking COVID-19 in U.S. counties, ' 'cities, and states in real time. J Am Med Inform Assoc. ' '2020;27(7):1121–5.', 'volume': '27', 'year': '2020'}, { 'DOI': '10.1016/j.ejphar.2020.173644', 'author': 'C Stasi', 'doi-asserted-by': 'publisher', 'journal-title': 'Eur J Pharmacol', 'key': '511_CR7', 'unstructured': 'Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An ' 'overview. Eur J Pharmacol. 2020. ' 'https://doi.org/10.1016/j.ejphar.2020.173644.', 'year': '2020'}, { 'DOI': '10.1016/j.ijid.2020.10.069', 'author': 'S Joshi', 'doi-asserted-by': 'publisher', 'first-page': '501', 'journal-title': 'Int J Infect Dis', 'key': '511_CR8', 'unstructured': 'Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role ' 'of favipiravir in the treatment of COVID-19. Int J Infect Dis. ' '2021;102:501–8.', 'volume': '102', 'year': '2021'}, { 'DOI': '10.1186/s13054-020-2818-6', 'author': 'AC Cunningham', 'doi-asserted-by': 'publisher', 'first-page': '91', 'issue': '1', 'journal-title': 'Crit Care', 'key': '511_CR9', 'unstructured': 'Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new ' 'challenges. Crit Care. 2020;24(1):91. ' 'https://doi.org/10.1186/s13054-020-2818-6.', 'volume': '24', 'year': '2020'}, { 'DOI': '10.1016/j.scitotenv.2020.138817', 'author': 'Z Ceylan', 'doi-asserted-by': 'publisher', 'journal-title': 'Sci Total Environ', 'key': '511_CR10', 'unstructured': 'Ceylan Z. Estimation of COVID-19 prevalence in Italy, Spain, and France. ' 'Sci Total Environ. 2020;729: 138817.', 'volume': '729', 'year': '2020'}, { 'DOI': '10.1016/j.psep.2020.05.029', 'author': 'AI Saba', 'doi-asserted-by': 'publisher', 'first-page': '1', 'journal-title': 'Process Saf Environ Prot', 'key': '511_CR11', 'unstructured': 'Saba AI, Elsheikh AH. Forecasting the prevalence of COVID-19 outbreak in ' 'Egypt using nonlinear autoregressive artificial neural networks. Process ' 'Saf Environ Prot. 2020;141:1–8.', 'volume': '141', 'year': '2020'}, { 'DOI': '10.1016/j.clim.2020.108448', 'author': 'S Felsenstein', 'doi-asserted-by': 'publisher', 'journal-title': 'Clin Immunol', 'key': '511_CR12', 'unstructured': 'Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: immunology ' 'and treatment options. Clin Immunol. 2020;215: 108448.', 'volume': '215', 'year': '2020'}, { 'DOI': '10.1615/CritRevTherDrugCarrierSyst.2021035392', 'author': 'T Haider', 'doi-asserted-by': 'publisher', 'first-page': '75', 'issue': '3', 'journal-title': 'Crit Rev Ther Drug Carrier Syst', 'key': '511_CR13', 'unstructured': 'Haider T, Gour V, Pandey V, Kanwar IL, Tiwari R, Vishwakarma M, et al. ' 'COVID-19 infection: targeting possibilities for treatment. Critical ' 'reviews™ in therapeutic drug carrier systems. Crit Rev Ther Drug Carrier ' 'Syst. 2021;38(3):75–115.', 'volume': '38', 'year': '2021'}, { 'DOI': '10.1016/j.medj.2020.06.001', 'author': 'J Magagnoli', 'doi-asserted-by': 'publisher', 'first-page': '11', 'issue': '1', 'journal-title': 'Med', 'key': '511_CR14', 'unstructured': 'Magagnoli J, Narendran S, Pereira F, Cummings TH, Hardin JW, Sutton SS, ' 'et al. Outcomes of hydroxychloroquine usage in United States veterans ' 'hospitalized with Covid-19. Med. 2020;1(1):11.', 'volume': '1', 'year': '2020'}, { 'DOI': '10.1002/14651858.CD014962', 'author': 'K Ansems', 'doi-asserted-by': 'publisher', 'first-page': 'CD014962', 'issue': '8', 'journal-title': 'Cochrane Database Syst Rev', 'key': '511_CR15', 'unstructured': 'Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, et ' 'al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst ' 'Rev. 2021;8(8):CD014962. https://doi.org/10.1002/14651858.CD014962.', 'volume': '8', 'year': '2021'}, { 'DOI': '10.1186/s12879-020-05698-w', 'author': 'M Nojomi', 'doi-asserted-by': 'publisher', 'first-page': '1', 'issue': '1', 'journal-title': 'BMC Infect Dis', 'key': '511_CR16', 'unstructured': 'Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, et al. ' 'Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled ' 'trial. BMC Infect Dis. 2020;20(1):1–10.', 'volume': '20', 'year': '2020'}, { 'DOI': '10.1016/j.ejphar.2020.173372', 'author': 'P Chibber', 'doi-asserted-by': 'publisher', 'journal-title': 'Eur J Pharmacol', 'key': '511_CR17', 'unstructured': 'Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the ' 'possible treatment of COVID-19: a review. Eur J Pharmacol. 2020;883: ' '173372.', 'volume': '883', 'year': '2020'}, { 'DOI': '10.1016/j.jiph.2021.08.030', 'author': 'A Assiri', 'doi-asserted-by': 'publisher', 'first-page': '1274', 'issue': '9', 'journal-title': 'J Infect Public Health', 'key': '511_CR18', 'unstructured': 'Assiri A, Iqbal MJ, Mohammed A, Alsaleh A, Assiri A, Noor A, et al. ' 'COVID-19 related treatment and outcomes among COVID-19 ICU patients: a ' 'retrospective cohort study. J Infect Public Health. 2021;14(9):1274–8.', 'volume': '14', 'year': '2021'}, { 'author': 'A Ismail', 'first-page': '16', 'issue': '2', 'journal-title': 'Malays J Public Health Med', 'key': '511_CR19', 'unstructured': 'Ismail A, Jamil AT, Rahman AFA, Bakar JMA, Saad NM, Saadi H. The ' 'implementation of Hospital Information System (HIS) in tertiary ' 'hospitals in Malaysia: a qualitative study. Malays J Public Health Med. ' '2010;10(2):16–24.', 'volume': '10', 'year': '2010'}, { 'DOI': '10.1503/cmaj.200645', 'author': 'Z Ye', 'doi-asserted-by': 'publisher', 'first-page': 'E756', 'issue': '27', 'journal-title': 'CMAJ', 'key': '511_CR20', 'unstructured': 'Ye Z, Wang Y, Colunga-Lozano LE, Prasad M, Tangamornsuksan W, Rochwerg ' 'B, et al. Efficacy and safety of corticosteroids in COVID-19 based on ' 'evidence for COVID-19, other coronavirus infections, influenza, ' 'community-acquired pneumonia and acute respiratory distress syndrome: a ' 'systematic review and meta-analysis. CMAJ. 2020;192(27):E756–67.', 'volume': '192', 'year': '2020'}, { 'DOI': '10.1016/j.tmaid.2020.101791', 'author': 'J-C Lagier', 'doi-asserted-by': 'publisher', 'journal-title': 'Travel Med Infect Dis', 'key': '511_CR21', 'unstructured': 'Lagier J-C, Million M, Gautret P, Colson P, Cortaredona S, ' 'Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated ' 'with hydroxychloroquine/azithromycin and other regimens in Marseille, ' 'France: a retrospective analysis. Travel Med Infect Dis. 2020;36: ' '101791.', 'volume': '36', 'year': '2020'}, { 'DOI': '10.1007/s40199-020-00353-w', 'author': 'E Vahedi', 'doi-asserted-by': 'publisher', 'first-page': '507', 'issue': '2', 'journal-title': 'DARU J Pharm Sci', 'key': '511_CR22', 'unstructured': 'Vahedi E, Ghanei M, Ghazvini A, Azadi H, Izadi M, Panahi Y, et al. The ' 'clinical value of two combination regimens in the Management of Patients ' 'Suffering from Covid-19 pneumonia: a single centered, retrospective, ' 'observational study. DARU J Pharm Sci. 2020;28(2):507–16.', 'volume': '28', 'year': '2020'}, { 'DOI': '10.1001/jama.2020.8630', 'author': 'ES Rosenberg', 'doi-asserted-by': 'publisher', 'first-page': '2493', 'issue': '24', 'journal-title': 'JAMA', 'key': '511_CR23', 'unstructured': 'Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, ' 'et al. Association of treatment with hydroxychloroquine or azithromycin ' 'with in-hospital mortality in patients with COVID-19 in New York State. ' 'JAMA. 2020;323(24):2493–502.', 'volume': '323', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2012410', 'author': 'J Geleris', 'doi-asserted-by': 'publisher', 'first-page': '2411', 'issue': '25', 'journal-title': 'N Engl J Med', 'key': '511_CR24', 'unstructured': 'Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. ' 'Observational study of hydroxychloroquine in hospitalized patients with ' 'Covid-19. N Engl J Med. 2020;382(25):2411–8.', 'volume': '382', 'year': '2020'}, { 'DOI': '10.1016/j.ijid.2020.06.099', 'author': 'S Arshad', 'doi-asserted-by': 'publisher', 'first-page': '396', 'journal-title': 'Int J Infect Dis', 'key': '511_CR25', 'unstructured': 'Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et ' 'al. Treatment with hydroxychloroquine, azithromycin, and combination in ' 'patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396–403.', 'volume': '97', 'year': '2020'}, { 'DOI': '10.1001/jamanetworkopen.2021.3071', 'author': 'BT Garibaldi', 'doi-asserted-by': 'publisher', 'first-page': 'e213071', 'issue': '3', 'journal-title': 'JAMA Netw Open', 'key': '511_CR26', 'unstructured': 'Garibaldi BT, Wang K, Robinson ML, Zeger SL, Bandeen-Roche K, Wang M-C, ' 'et al. Comparison of time to clinical improvement with vs without ' 'remdesivir treatment in hospitalized patients with COVID-19. JAMA Netw ' 'Open. 2021;4(3):e213071.', 'volume': '4', 'year': '2021'}, { 'DOI': '10.1016/j.ijantimicag.2020.106114', 'author': 'S Tong', 'doi-asserted-by': 'publisher', 'issue': '3', 'journal-title': 'Int J Antimicrob Agents', 'key': '511_CR27', 'unstructured': 'Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, et al. Ribavirin therapy for ' 'severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents. ' '2020;56(3): 106114.', 'volume': '56', 'year': '2020'}, { 'DOI': '10.1007/s11739-021-02655-6', 'author': 'A Bahl', 'doi-asserted-by': 'publisher', 'first-page': '1593', 'issue': '6', 'journal-title': 'Intern Emerg Med', 'key': '511_CR28', 'unstructured': 'Bahl A, Johnson S, Chen N-W. Timing of corticosteroids impacts mortality ' 'in hospitalized COVID-19 patients. Intern Emerg Med. ' '2021;16(6):1593–603.', 'volume': '16', 'year': '2021'}, { 'DOI': '10.1097/SHK.0000000000001738', 'author': 'J Li', 'doi-asserted-by': 'publisher', 'first-page': '215', 'issue': '2', 'journal-title': 'Shock', 'key': '511_CR29', 'unstructured': 'Li J, Liao X, Zhou Y, Wang L, Yang H, Zhang W, et al. Comparison of ' 'associations between glucocorticoids treatment and mortality in COVID-19 ' 'patients and SARS patients: a systematic review and meta-analysis. ' 'Shock. 2021;56(2):215–28.', 'volume': '56', 'year': '2021'}, { 'DOI': '10.1016/j.phrs.2020.104872', 'author': 'H Zhong', 'doi-asserted-by': 'publisher', 'journal-title': 'Pharmacol Res', 'key': '511_CR30', 'unstructured': 'Zhong H, Wang Y, Zhang Z-L, Liu Y-X, Le K-J, Cui M, et al. Efficacy and ' 'safety of current therapeutic options for COVID-19-lessons to be learnt ' 'from SARS and MERS epidemic: a systematic review and meta-analysis. ' 'Pharmacol Res. 2020;157: 104872.', 'volume': '157', 'year': '2020'}, { 'DOI': '10.1038/s41598-021-90551-6', 'author': 'S Hassanipour', 'doi-asserted-by': 'publisher', 'first-page': '1', 'issue': '1', 'journal-title': 'Sci Rep', 'key': '511_CR31', 'unstructured': 'Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, ' 'Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment ' 'of COVID-19: a systematic review and meta-analysis of clinical trials. ' 'Sci Rep. 2021;11(1):1–11.', 'volume': '11', 'year': '2021'}, { 'DOI': '10.1093/cid/ciaa954', 'author': 'EC Somers', 'doi-asserted-by': 'publisher', 'first-page': 'e445', 'issue': '2', 'journal-title': 'Clin Infect Dis', 'key': '511_CR32', 'unstructured': 'Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. ' 'Tocilizumab for treatment of mechanically ventilated patients with ' 'COVID-19. Clin Infect Dis. 2021;73(2):e445–54.', 'volume': '73', 'year': '2021'}, { 'DOI': '10.1016/j.jiph.2020.12.017', 'author': 'R Guner', 'doi-asserted-by': 'publisher', 'first-page': '365', 'issue': '3', 'journal-title': 'J Infect Public Health', 'key': '511_CR33', 'unstructured': 'Guner R, Hasanoglu I, Kayaaslan B, Aypak A, Akinci E, Bodur H, et al. ' 'Comparing ICU admission rates of mild/moderate COVID-19 patients treated ' 'with hydroxychloroquine, favipiravir, and hydroxychloroquine plus ' 'favipiravir. J Infect Public Health. 2021;14(3):365–70.', 'volume': '14', 'year': '2021'}, { 'author': 'M Adeli', 'first-page': '675', 'issue': '8', 'journal-title': 'Journal Mil Med', 'key': '511_CR34', 'unstructured': 'Adeli M, Fesharaki MG. Evaluation of COVID-19 treatment outcomes in a ' 'military hospital and its comparison with a nonmilitary hospital. ' 'Journal Mil Med. 2021;23(8):675–83.', 'volume': '23', 'year': '2021'}, { 'DOI': '10.12788/jhm.3497', 'author': 'MJ Keller', 'doi-asserted-by': 'publisher', 'first-page': '489', 'issue': '8', 'journal-title': 'J Hosp Med', 'key': '511_CR35', 'unstructured': 'Keller MJ, Kitsis EA, Arora S, Chen JT, Agarwal S, Ross MJ, et al. ' 'Effect of systemic glucocorticoids on mortality or mechanical ' 'ventilation in patients with COVID-19. J Hosp Med. 2020;15(8):489–93.', 'volume': '15', 'year': '2020'}, { 'DOI': '10.1016/j.jsps.2020.09.019', 'author': 'SH Almazrou', 'doi-asserted-by': 'publisher', 'first-page': '1877', 'issue': '12', 'journal-title': 'Saudi Pharmaceutical Journal', 'key': '511_CR36', 'unstructured': 'Almazrou SH, Almalki ZS, Alanazi AS, Alqahtani AM, Alghamd SM. Comparing ' 'the impact of Hydroxychloroquine based regimens and standard treatment ' 'on COVID-19 patient outcomes: a retrospective cohort study. Saudi ' 'Pharmaceutical Journal. 2020;28(12):1877–82.', 'volume': '28', 'year': '2020'}], 'reference-count': 36, 'references-count': 36, 'relation': {}, 'resource': {'primary': {'URL': 'https://joppp.biomedcentral.com/articles/10.1186/s40545-023-00511-w'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Pharmacy', 'Health Policy'], 'subtitle': [], 'title': 'Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in ' 'Sanandaj hospitals: a retrospective cohort study', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'volume': '16'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit